Stockwinners Market Radar for May 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:28 EDT Hostess Brands CEO: We are focused on growth and innovation - In an interview on CNBC's Mad Money, Andy Callahan said Hostess has a portfolio that is poised for growth. The company is focused on innovation, quality and growth. The repeat rate of Hostess' new users is twice that of the category, he noted. According to Callahan, the company is building a "powerhouse of snacking" He admitted costs are high, but price increases would only be used as a last resort. "We're resilient when it comes to recessions," he added.

17:56 EDT FDA approves Eli Lilly's Mounjaro injection for treatment of type 2 diabetes - The U.S. Food and Drug Administration approved Mounjaro injection, Eli Lilly and Company's new once-weekly GIP and GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. "Mounjaro delivered superior and consistent A1C reductions against all of the comparators throughout the SURPASS program, which was designed to assess Mounjaro's efficacy and safety in a broad range of adults with type 2 diabetes who could be treated in clinical practice. The approval of Mounjaro is an exciting step forward for people living with type 2 diabetes given the results seen in these clinical trials," said Juan Pablo Frias, M.D., Medical Director, National Research Institute and Investigator in the SURPASS program.

17:35 EDT Trian exists Comcast position, increases stake in Invesco - Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of March 31, 2022. Trian exited one position during the quarter, Comcast (CMCSA). Trian increased its stake in five holdings, including by size of previous position, Invesco (IVZ), Mondelez (MDLZ), General Electric (GE), Janus Henderson (JHG), and Ferguson (FERG). Trian reduced its stake in two holdings, including by size of previous position, Sysco (SYY) and Procter & Gamble (PG). Trian's top holdings as of March 31, in order of size, were Ferguson, Invesco, Janus Henderson, Sysco, and Wendy's (WEN).

17:15 EDT Soros buys Lucid, exits GM in Q1 - George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of March 31, 2022. The fund's 28 new buys during the first quarter included, by size of position, Zynga (ZNGA), Freshworks Class A (FRSH), Atlassian (TEAM), Lucid (LCID), and TJX (TJX). The fund exited 48 holdings during the quarter, including by size of previous position Activision Blizzard (ATVI), General Motors (GM), Ally Financial (ALLY), Uber (UBER), and Marqeta (MQ). Soros increased its stake in 19 holdings, including by size of previous position Cerner (CERN), Alphabet Class A (GOOGL), JPMorgan (JPM), Nike (NKE), and Accenture (ACN). The fund reduced its stake in 23 holdings, including by size of previous position D.R. Horton (DHI), Liberty Broadband Class C (LBRDK), Aramark (ARMK), Proterra (PTRA), and Elanco Animal Health (ELAN). The fund's top holdings as of March 31, in order of size, were Rivian (RIVN), Liberty Broadband Class C, Cerner, Amazon (AMZN), and D.R. Horton.

16:37 EDT Vulcan Materials provides update on Mexican SAC TUN operations - Vulcan Materials provided an update with respect to its Mexican SAC TUN operations. Vulcan Materials confirmed that the Mexican government has suspended the three-year customs permit granted in March 2022 to the Mexican subsidiary of the company and has begun a proceeding that could result in the revocation of that permit. A decision to maintain or revoke the permit will be made within weeks. This routinely renewed permit had been recently granted for customs purposes at the port terminal within our property. The port terminal is operated by the company pursuant to a concession that is valid through 2037. The permit enables Vulcan's subsidiary to export its production to the United States; however, absent the customs permit no export or import operations of any kind may be conducted by any entity at the port terminal. As with the arbitrary shutdown orders to immediately cease underwater quarrying and extraction operations received on May 5, Vulcan strongly believes that this latest action by Mexico is arbitrary and illegal. These adverse measures have the effect of shutting down the operations of SAC TUN in Quintana Roo, Mexico. Vulcan has sought injunctive relief in Mexico that, if granted and complied with, would enable the company to resume normal operations including the extraction, processing and export of materials. Should the company be unable to fully operate in Mexico for the balance of 2022, the potential EBITDA impact would range from $80M-$100M, which would approximate 5% of Vulcan's Adjusted EBITDA guidance of $1.72B-$1.82B for 2022. The company intends to vigorously pursue all lawful avenues available to it in order to protect its rights, under both Mexican and international law, and resume normal operations as soon as permitted. The company has quarried limestone legally in Mexico - on land that it owns - for over 30 years. Vulcan has the right to maintain full ownership of its properties, owns the limestone reserves in the same, and complies and has always complied with Mexican law, including the laws and permitting regulating our operations from which we service our customers in the United States, Mexico and the Caribbean basin. Since late 2018, Vulcan Materials has been engaged in a NAFTA arbitration with Mexico over Mexico's repudiation of an agreement to unlock a portion of Vulcan's aggregates reserves in Mexico and the arbitrary shutdown of a different portion of the company's quarrying operations there. A hearing took place in July 2021, and a decision is expected in the second half of 2022. This decision may be delayed if the Tribunal accepts the company's recent request to hear the new NAFTA violations related to Mexico's latest measures. Vulcan has continued to engage with government officials to pursue an amicable resolution of the dispute while awaiting the final resolution from the NAFTA tribunal.

16:31 EDT Priority Technology announces retirement of CFO Michael Vollkommer - Priority Technology announced the retirement of Michael Vollkommer, its CFO. Vollkommer, who has been the company's CFO since December 2018, will retire from Priority on September 1. Subsequently, Vollkommer will remain with the company in an advisory capacity to ensure a smooth transition and to assist in executing strategic projects going forward. The company has begun its search for Vollkommer's replacement and expects to name the next CFO during the third quarter.

16:02 EDT Eargo receives Nasdaq non-compliance letter - Eargo announced the company received a letter from The Nasdaq Stock Market LLC notifying the company that because it remains delinquent in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and because it is delinquent in filing its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, it has not regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission. Previously, Nasdaq had granted the company an extension until May 16, 2022 to regain compliance. The Letter indicated that the company's securities would be subject to delisting on May 23, 2022 as a result of the company's non-compliance, unless on or before May 19, 2022 the company requests a hearing before the Nasdaq Hearings Panel and requests an extended stay of suspension or delisting.

15:35 EDT FDA approves Eli Lilly's Mounjaro for type 2 diabetes - The U.S. Food and Drug Administration approved Mounjaro injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies, the FDA stated in its announcement of the approval. The FDA granted the approval of Mounjaro to Eli Lilly. Reference Link

15:15 EDT Twitter CEO says expects deal to close, but 'prepared for all scenarios' - Twitter CEO Parag Agrawal said in a series of tweets: "A lot has happened over the past several weeks. I've been focused on the company and haven't said much publicly during this time, but I will now. We announced changes to our leadership team and operations yesterday. Changes impacting people are always hard. And some have been asking why a 'lame-duck' CEO would make these changes if we're getting acquired anyway. The short answer is very simple: While I expect the deal to close, we need to be prepared for all scenarios and always do what's right for Twitter. I'm accountable for leading and operating Twitter, and our job is to build a stronger Twitter every day. No one at Twitter is working just to keep the lights on. We take pride in our work. Regardless of the company's future ownership, we're here improving Twitter as a product and business for customers, partners, shareholders, and all of you... So what can you expect from me going forward? I'm still focused on doing the job, and that includes making hard decisions as needed. I will continue to embrace the deep complexities of our service and our business. And you can expect more change for the better." Reference Link

14:43 EDT Volta says 'substantial doubt' about ability to continue as going concern - According to a regulatory filing, Legacy Volta entered into a Business Combination Agreement with Tortoise Acquisition Corp. II. on February 7, 2021 and following the Closing, began trading on the New York Stock Exchange. The company received net cash proceeds of over $350.1M in cash following the Reverse Recapitalization through the sale of shares of Volta common stock. However, additional cash obligations in the next twelve months are expected to include investments in the operations and purchases to expand the business. Management has considered conditions and events which provide substantial doubt about the company's ability to continue as a going concern over the 12 months following the issuance of the condensed consolidated financial statements. The company concluded that there is substantial doubt about the company's ability to continue as a going concern in the next twelve months based on reasonable information available to us as of the date of this analysis. No assurances can be provided that additional funding will be available at terms acceptable to the company, if at all. If the company is unable to raise additional capital, the company may significantly curtail its operations, modify strategic plans and/or dispose of certain operations or assets.

13:32 EDT Blue Ocean says court granted order to stop Global Cord Blood deal for Cellenkos - Blue Ocean Structure Investment Company, a significant shareholder of Global Cord Blood Corporation, announced that the Grand Court of the Cayman Islands granted injunction order to stop Global Cord Blood's planned acquisition of Cellenkos. Blue Ocean's investment in Global Cord Blood represents an ownership position of approximately 65% of the company's shares.The injunction order was obtained on an ex parte basis. There will be a further hearing in respect of this order on May 24, the firm stated.

13:01 EDT Baker Hughes reports U.S. rig count up 9 to 714 rigs - Baker Hughes reports that the U.S. rig count is up 9 from last week to 714 with oil rigs up 6 to 563, gas rigs up 3 to 149 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 261 rigs from last year's count of 453 with oil rigs up 211, gas rigs up 49 and miscellaneous rigs down 1 to 1. The U.S. Offshore Rig Count is up 1 to 18, up 3 year-over-year. The Canada Rig Count is down 3 from last week to 88, with oil rigs down 5 to 37, gas rigs up 2 to 51. The Canada Rig Count is up 29 rigs from last year's count of 59, with oil rigs up 12, gas rigs up 17.

12:39 EDT Abbott says could restart Sturgis formula site within 2 weeks, pending approval - Abbott provided an infant formula update that states in part: "Since the recall, one of our priorities has been to mitigate the supply issues. In particular we've been focusing on production in our Cootehill, Ireland, facility to serve state Special Supplemental Nutrition Program for Women, Infants and Children consumers. Abbott has been working with the USDA and WIC agencies and paying rebates on competitive products in states where Abbott holds the WIC contract, when Similac is not available. Abbott will continue to pay rebates for competitive products through August. This means program participants will continue to be able to obtain formula, free of charge whether it is Similac or formula from another manufacturer. We know that the recall has worsened the industry-wide infant formula shortage, and we have been working to get getting as much product into the hands of parents as we can... At the same time, we have been working to address the FDA's 483 observations so we can restart operations at the Sturgis, Mich., facility. We immediately began implementing corrective actions and subject to FDA approval, we could restart our Sturgis, Mich., site within two weeks. We are confident that we can continue to produce safe, high-quality infant formula at all of our facilities as we have been doing for millions of babies around the world for decades." Reference Link

12:00 EDT Daily S&P Biotech Bear 3x Shares falls -16.6% - Daily S&P Biotech Bear 3x Shares is down -16.6%, or -$12.12 to $61.09.

12:00 EDT Asana rises 22.9% - Asana is up 22.9%, or $4.56 to $24.43.

12:00 EDT Lightspeed rises 26.8% - Lightspeed is up 26.8%, or $4.33 to $20.50.

11:11 EDT U.S. video game spending fell 8% y/y in April, says NPD - NPD analyst Mat Piscatella said that April 2022 consumer spending across video game hardware, content and accessories declined 8% when compared to a year ago, to $4.3B. Hardware gains were unable to offset declines in content and accessories spending. Year-to-date 2022 spending is 8% lower than the same period a year ago, at $18.3B. The market has experienced 6 consecutive months of YoY declines, Piscatella noted. Video game hardware dollar sales in April increased 16% when compared to a year ago, to $343M, due to improved supply of PlayStation 5 (SONY) and Xbox Series (MSFT) consoles. Year-to-date spending on hardware fell 9%, to $1.5B. The Nintendo Switch (NTDOY) featured the highest unit sales of any hardware platform for both April and 2022 year-to-date. Xbox Series ranked 2nd in units sold during both time periods. Lifetime unit sales of Nintendo Switch have now surpassed those of PlayStation 4, making it the 4th highest unit selling console in U.S. history, and the 6th highest unit selling video game hardware platform overall. In console it trails only PS2, Xbox 360 and Wii. PlayStation 5 led April in hardware dollar sales, trailed closely by Xbox Series and Nintendo Switch. Xbox Series has generated the highest hardware dollars of any platform year-to-date, followed by PlayStation 5 and Nintendo Switch. Other publicly traded companies in the space include Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME), Take-Two (TTWO), Tencent (TCEHY) and Ubisoft (UBSFY). Reference Link

10:39 EDT HG Vora Capital discloses 9.9% stake in Ryder, offers to buy rest for $86/share - HG Vora Capital disclosed in a regulatory filing that the fund presently holds approximately 9.9% of Ryder System's common stock, which it acquired because it believes the shares of common stock are undervalued and represent an attractive investment opportunity. On May 13, the fund sent a letter proposing to acquire all of the outstanding shares of common stock not currently held at a purchase price of $86 per share paid in cash at closing. The purchase price represents a 24.8% premium to the 30-day trailing volume weighted average price of the common stock and a 20.3% premium to the closing price of the common stock on May 12, the filing noted. The fund anticipates funding the purchase price with capital provided by funds managed by the reporting person and an alternative investment manager with over $250B in assets, as well as certain other lender commitments to be delivered concurrent with signing a definitive agreement to acquire the company. "The proposed acquisition is subject to, among other things, the fund's satisfaction with the results of due diligence regarding the financial outlook of the Fleet Management Solutions, Supply Chain Solutions and Dedicated Transportation Solutions businesses, as well as the evaluation of relevant commercial, legal, accounting and tax matters," the filing with the SEC stated.

10:35 EDT HG Vora Capital offers to acquire Ryder at $86 per share

10:27 EDT JE Cleantech Holdings Ltd trading resumes

10:17 EDT JE Cleantech Holdings Ltd trading halted, volatility trading pause

10:00 EDT Angel Oak Mortgage falls -11.7% - Angel Oak Mortgage is down -11.7%, or -$1.72 to $13.00.

10:00 EDT Lightspeed rises 18.1% - Lightspeed is up 18.1%, or $2.93 to $19.10.

10:00 EDT Endeavor Group rises 22.0% - Endeavor Group is up 22.0%, or $4.04 to $22.38.

09:53 EDT Alpine 4 Holdings' Quality Circuit Assembly receives $4.8M in orders - Alpine 4 Holdings announces that its subsidiary, Quality Circuit Assembly has secured $4.8 million dollars in new purchase orders for cleanroom monitoring systems.

09:47 EDT Daily S&P Biotech Bear 3x Shares falls -10.0% - Daily S&P Biotech Bear 3x Shares is down -10.0%, or -$7.31 to $65.90.

09:47 EDT Figs falls -23.8% - Figs is down -23.8%, or -$3.05 to $9.80.

09:47 EDT Toast rises 15.2% - Toast is up 15.2%, or $2.17 to $16.45.

09:45 EDT Healthcare Capital Corp trading resumes

09:36 EDT DarioHealth trading resumes

09:31 EDT Opiant Pharmaceuticals Inc trading halted, volatility trading pause

09:30 EDT Healthcare Capital Corp trading halted, volatility trading pause

09:18 EDT 22nd Century announces acquisition of GVB Biopharma - 22nd Century Group announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization, CDMO, GVB is believed to be one of the largest providers of hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide based on total tonnage. James Mish, chief executive officer of 22nd Century Group, stated: "GVB represents a transformational acquisition for 22nd Century that will enable us to rapidly grow our hemp/cannabis franchise. GVB is one of the largest CBD suppliers globally, possessing innovative, vertically integrated cannabinoid product manufacturing technologies driving industry leading scale and cost efficiency. In addition to immediately expanding our hemp/cannabis franchise capabilities, GVB represents an opportunity to double our revenue and internalize a comprehensive contract manufacturing and extraction platform which can be used to directly and exclusively monetize our differentiated and proprietary hemp/cannabis plant genetics and intellectual property. We are enthusiastic to begin working with the highly regarded and very experienced management team at GVB."

09:16 EDT Flushing Financial leases new Suffolk County location - Flushing Financial announced it has leased a new Suffolk County location in the Hauppauge Industrial Park. The Bank plans to open this new, full-service branch location later this year. John Buran stated, "Our brand was first introduced to the Suffolk County market through our acquisition of Empire National Bank. This new Hauppauge location enables us to build upon our Suffolk County presence and further develop relationships within the market. The location is ideal for serving the business community within and around the Hauppauge Industrial Park."

09:14 EDT Crispr to present new clinical data on Anti-CD70 CAR-T Therapy for CTX130 at EHA - The company states: "CRISPR Therapeutics announced that an abstract providing safety and efficacy data from the ongoing CTX130 clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association 2022 Hybrid Congress, taking place June 9 - 12, 2022, at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online. This will be the first clinical data presented from the CTX130 program." The abstract is available here: Reference Link

09:06 EDT Palisade Bio announces expected upcoming milestones - Q4 2022: Phase 2 enrollment completion; 1H 2023: Phase 2 study completion; 2H 2023: Report Phase 2 topline results

09:04 EDT American International Holdings announces 1-for-60 reverse stock split - American International announces it has effected a 1-for-60 reverse split of its common stock effective May 12, 2022. Commencing with the opening of trading on the OTCQB Market maintained by OTC Markets on May 13, 2022, the Company's common stock will trade on a post-split basis under the symbol 'AMIHD' for a period of 20 business days including the effective date of the reverse stock split. After the conclusion of the 20-business day period, the Company's common stock will resume trading under its previous ticker symbol "AMIH". As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 02687R205 and every 60 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share.

09:03 EDT Usio announces share repurchase program to buy up to $4M of its stock - Usio announced that its Board of Directors has authorized the repurchase of up to $4M of the Company's common stock from time to time on the open market, block transactions or in privately negotiated transactions. The program can begin as early as May 16, 2022 and will be available until all funds are exhausted or May 15, 2025 unless terminated earlier by the Company. "Usio's management team and Board of Directors believe our current stock price is not reflective of our rapid growth that has delivered seven consecutive quarters of revenue growth, enhanced our long-term growth potential and does not reflect a reasonable current valuation relative to comparable companies in the Fintech and payments industry," stated Louis Hoch, President and CEO of Usio. "We intend to utilize our existing cash and our ability to generate adjusted operating cash flow to fund the repurchase program, which we believe is our current best use of cash to create value for our shareholders."

09:01 EDT Universal Logistics launches Dutch auction tender offer to purchase 100K shares - Universal Logistics Holdings announced the commencement of a modified "Dutch auction" tender offer to purchase up to 100,000 shares, or about 0.4%, of its outstanding common stock using funds borrowed under its existing line of credit and available cash, at a price of not less than $25.00 and not more than $28.00 per share. The tender offer will expire at 5:00 p.m., Eastern Time, on June 15, unless extended or withdrawn. Universal's Board of Directors determined that it is in the company's best interest to repurchase shares at this time given Universal's cash position and stock price.

09:00 EDT Encompass Health to build 60-bed inpatient rehabilitation hospital in Houston - Encompass Health plans to build a freestanding, 60-bed inpatient rehabilitation hospital in Houston, Texas. The future hospital will serve patients recovering from debilitating illnesses and injuries, including strokes and other neurological disorders, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions. The planned hospital, once opened, will become part of Encompass Health's national network of inpatient rehabilitation hospitals and home health and hospice agencies.

08:46 EDT Charles Schwab reports $7.28T total client assets at end of April - The Charles Schwab Corporation released its Monthly Activity Report today. Company highlights for the month of April 2022 include: Core net new assets brought to the company by new and existing clients totaled negative $9.2 billion. Net new assets excluding mutual fund clearing totaled negative $6.5 billion. These flows reflect client cash disbursements during tax season. Total client assets were $7.28 trillion as of month-end April, down 1% from April 2021 and down 7% compared to March 2022. Average interest-earning assets were $636.7 billion in April, up 21% from April 2021 and down 1% compared to March 2022. CFO Peter Crawford commented, "Client cash disbursements during this year's tax season were the highest we've ever seen at Schwab. These outflows include the impact of client portfolio actions taken during 2021, a year marked by strong equity market performance and robust trading activity. Such seasonal activity is distinct from flows within client accounts rebalancing their cash positions between daily liquidity and investments such as money market funds. This rebalancing, or sorting, activity tends to occur as an extended period of low interest rates shifts into a rising rate environment and clients refresh their allocations. While the Federal Reserve has taken initial steps to move interest rates higher thus far in 2022, short rates are just now approaching the point where we'd expect to see clients start to rebalance their cash positions. Assuming the Fed's tightening cycle remains consistent with current forecasts, we believe we could see rebalancing activity begin to surface before the end of the second quarter. Such actions may lead to a slight decline in balance sheet assets from current levels over the next quarter or two. As we help clients navigate this environment, we remain confident that the successful execution of our 'Through Clients' Eyes' strategy, coupled with our all-weather financial model, will support strong long-term growth - in our client base, and in value for our stockholders."

08:34 EDT Ageagle Aerial Systems announces enhancements to Measure Ground Control - AgEagle Aerial Systems announced new and enhanced technological features and capabilities of Measure Ground Control, helping to drive greater value from autonomous drone operations for enterprise customers and professional drone service providers spanning a wide range of industries. "Ground Control was literally built from the ground-up, working closely with customers to intimately understand their unique needs, frustrations and challenges and to solve real human problems. As a result, our performance-driven software platform avails scalable, autonomous drone programs that are incredibly easy to deploy and manage and from which our customers' can aggregate vast amounts of data and deep insight necessary to make important, well-informed decisions in their day-to-day business operations - be it an Energy, Infrastructure, Agriculture or other commercial enterprise," stated Barrett Mooney, Chairman and CEO of AgEagle.

08:33 EDT Checkpoint Therapeutics receives PIP waivers for cosibelimab from EMA - Checkpoint Therapeutics announced that it has received Pediatric Investigation Plan, PIP, product-specific waivers from the European Medicines Agency, EMA. and the U.K. Medicines & Healthcare products Regulatory Agency, MHRA, for cosibelimab in cutaneous squamous cell carcinoma, cSCC. Following the announcement of positive topline data from Checkpoint's registration-enabling clinical trial in January 2022, a U.S. Biologics License Application, BLA, submission for cosibelimab is planned for later this year, to be followed by marketing authorization applications, MAAs, in Europe. "These waivers from the EMA and MHRA are important milestones in the European regulatory process for cosibelimab in cSCC," said James Oliviero, President and Chief Executive Officer of Checkpoint Therapeutics. "Such PIP waivers enable us to proceed more quickly and cost-effectively when advancing our marketing approval applications with the EMA and MHRA, avoiding the significant time and expense required to conduct a pediatric clinical study in Europe. As such, these PIP waivers enhance the value of the cosibelimab program in Europe for Checkpoint and potential partners."

08:32 EDT Greenlane enters agreement with Universal Distribution for Latin America - Greenlane Holdings entered into a distribution agreement with Universal Distribution LATAM to distribute its proprietary portfolio of house brands in Latin America. Under the terms of the agreement, Greenlane has granted Universal Distribution: the exclusive right to promote, market, distribute and sell the Greenlane Brands to retailers for resale in Chile, Uruguay and Argentina; the non-exclusive right to promote, market, distribute and sell the Greenlane Brands via all wholesale channels in other territories in South America, Central America, and Mexico. As part of the agreement, Universal Distribution also has been granted the non-exclusive right to sell certain third-party brand products. Universal Distribution has committed to the following sales targets within the first three years of the agreement to maintain exclusivity, consisting of both Greenlane Brands and select high-velocity third-party brand products: Year 1: at least $1.5 million of Greenlane Brands and third-party products; Year 2: at least $1.9 million of Greenlane Brands and third-party products; Year 3: at least $2.4 million of Greenlane Brands and third-party products.

08:15 EDT NSW Government partners with Thoughtworks for digital birth certificates - Thoughtworks has been selected by the New South Wales Government to develop and deploy the world's first digital birth certificate which will provide citizens with highly-secure, anytime, anywhere access. Thoughtworks' appointment follows the NSW Government's announcement last year that it would be "spearheading a cross-jurisdictional project to develop a national Digital Birth Certificate" and is a key priority of the NSW Premier's Government Made Easy initiative. A digital birth certificate will help overcome many issues around the use of a physical identity document including durability, safekeeping and accessibility. The digital birth certificate is expected to be widely accepted by government, businesses, schools, and sporting organizations, making it faster and easier for citizens to apply for products and services.

08:12 EDT Acutus Medical completes enrollment in AcQForce Flutter IDE trial - Acutus Medical announced successful completion of patient enrollment in the company's AcQForce Flutter Investigational Device Exemption, IDE, clinical trial which enrolled 110 patients at 21 sites globally. The AcQForce Flutter trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter. Designed specifically to provide consistent, effective therapeutic solutions during cardiac ablation procedures, the AcQBlate FORCE system shows physicians, in real-time, how much contact force is being applied to the heart during ablations. "Completing enrollment in the AcQForce Flutter trial represents a significant advancement in our journey to enter the United States with a therapeutic technology for the treatment of atrial flutter," said David Roman, interim Chief Executive Officer and Chief Financial Officer of Acutus Medical. "Acutus has a strong history of partnering with physicians to bring innovative technology to the market to treat atrial arrhythmias, and we are thankful to our clinical trial sites, specifically the dedication and commitment of investigators and their staff, and to our clinical team for their collaboration in reaching this milestone."

08:12 EDT KB Home announces grand opening of Silverado - KB Home announced the grand opening of Silverado, a new townhome community in a San Diego County location. The new enclave of homes is situated on Smilax Road in Vista, California, just south of Highway 78 and convenient to Interstates 5 and 15. The transit-oriented community is also close to the Vista Transit Center SPRINTER hybrid rail station, providing easy access to San Diego County's major employment centers and attractions. Silverado is just minutes away from popular beaches, shopping, dining and entertainment as well as California State University San Marcos and Palomar College.

08:11 EDT Lantheus announces first patient dosed in Phase 2 trial of NM-01 - Lantheus announced the first patient has been dosed in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells, for its potential to identify patients who will respond to checkpoint inhibitor therapies. The PELICAN trial is an open-label, single-arm trial in non-small cell lung cancer, NSCLC, patients. The primary endpoint is the assessment of PD-L1 expression in primary tumor and metastatic lesions by NM-01 compared to immunohistochemistry. Other objectives will look at quantifying intra- and inter-tumoral heterogeneity of PD-L1 expression by NM-01, as well as establishing correlation with other diagnostic procedures. "The future potential for targeted imaging agents, like NM-01, to inform clinical decision-making in oncology is very exciting," said Jean-Claude Provost, MD, Interim Chief Medical Officer, Lantheus. "We are pleased to take this important step forward in the development of a novel imaging agent that is designed to provide new information to optimize the use of checkpoint inhibitor therapies, improve patient outcomes and limit the need for multiple biopsies to be performed over the course of checkpoint inhibitor treatment."

08:09 EDT Bionano Genomics announces participation at ACC - Bionano Genomics announced that it is participating in-person at the American Cytogenomics Conference, ACC. In addition to having six presentations that highlight the application of OGM in clinical genetics research, Bionano will host a user spotlight event at Augusta University, a center of excellence for OGM. Dr. Solheil Shams, chief informatics officer at Bionano, will present on the utilization of three new measures of genomic instability available in NxClinical v6.2 software to detect homologous recombination repair deficiency in solid tumors. In a spotlight talk immediately following the OGM scientific session, Dr. Alex Hastie, Bionano's vice president of clinical affairs, will present examples of research where OGM may complement next generation sequencing to potentially provide a more comprehensive analysis of the genome, for applications in genetic disease and cancer. At the conclusion of ACC, Bionano will host an interactive tour of an OGM center of excellence at the Georgia Esoteric Molecular Laboratory at Augusta University. "The lineup of content that will be presented on Bionano's solutions at ACC this year is world class. What makes our participation unique this year, is that we will have the combination of OGM products and our NxClinical software for attendees to view. We are focused on addressing their needs and now we can show them how, in person. After the show, we will be hosted at Augusta University where several scientists and cytogeneticists will join us for a hands-on experience of the journey that Dr. Ravi Kohle's lab has taken to become an OGM center of excellence," said Erik Holmlin, PhD, president and chief executive officer of Bionano.

08:08 EDT Outlook Therapeutics expects cash to provide funding into Q1 of 2023 - At March 31, 2022, Outlook Therapeutics had cash and cash equivalents of $58.4 million, compared to $70.2 million at December 31, 2021. Outlook Therapeutics' cash and cash equivalents on hand are expected to provide funding into the first calendar quarter of 2023. "We believe Outlook Therapeutics is in a strong financial position," stated Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics. "We have successfully accessed capital via our ATM program and plan to continue using this financing option, subject to market conditions. Also, we have initiated discussions with the holders of our unsecured notes to extend the maturity of these notes until 2024 after we begin generating revenue from LYTENAVA, if approved. With these steps, we believe we have charted a path that would allow Outlook Therapeutics to launch LYTENAVA without the need to raise significant additional capital."

08:07 EDT Outlook Therapeutics announces upcoming milestones - Receive PDUFA date from FDA; Continued progress with ongoing pre-launch commercial preparations in anticipation of potential approval for ONS-5010 in early 2023; and Completion in calendar 2022 of the NORSE SEVEN study evaluating Outlook Therapeutics' vial delivery system versus a pre-filled syringe of ONS-5010.

08:07 EDT Community Health deploys PeriWatch Vigilance maternal-fetal early warning system - Community Health Systems announced that its affiliated hospitals offering obstetrics services have deployed PeriWatch Vigilance, an artificial intelligence-based maternal-fetal early warning system. The technology, developed by perinatal software company, PeriGen, supports clinical decision-making and safety for mothers and babies during labor and delivery. Using artificial intelligence and machine learning for pattern recognition, Vigilance monitors maternal vital signs, fetal heart rate, uterine contractions and labor progression to help clinical teams more consistently identify potential issues and abnormalities earlier for faster intervention. The system can also consolidate and analyze labor and delivery data over time for multiple births to identify modifiable factors and opportunities for continuous safety and quality improvement. Community Health Systems and PeriGen will present early results following implementation of Vigilance at the IHI Patient Safety Congress next week, including improvements in two modifiable factors that can contribute to birth injuries.

08:03 EDT PolarityTE's SkinTE granted Regenerative Medicine Advanced Therapy Designation - PolarityTE announced that the FDA granted a Regenerative Medicine Advanced Therapy - RMAT - designation to SkinTE under the company's open IND. RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products, including human cellular and tissue-based therapies. Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development. The Agency has offered a multidisciplinary, comprehensive discussion between PolarityTE and the FDA regarding the SkinTE development program, including planned clinical trials and plans for expediting the manufacturing development strategy.

08:01 EDT Twitter off lows, remains down 11%, after Musk says 'still committed' to deal - Twitter (TWTR) shares are off their earlier lows, but remain down $5.01, or 11%, to $40.07 in pre-market trading after Elon Musk said in a series of tweets that his planned takeover deal is on hold but he remains "committed" to an acquisition. Shares of Tesla (TSLA) have also been volatile amid the tweets from the electric carmaker's founder and CEO.

07:48 EDT Cruiser Capital urges American Vanguard shareholders to vote for nominees - Cruiser Capital Master Fund, a top ten shareholder of American Vanguard Corporation, owning approximately 2.5% of AVD's outstanding shares, released a presentation to stockholders "outlining the urgent need to elevate American Vanguard following a decade of underperformance and poor corporate governance." Cruiser has nominated three directors for election to the AVD Board of Directors at the June 1, 2022, Annual Meeting of Stockholders. Cruiser Capital stated: "Real change is needed to address the long-term underperformance at American Vanguard and we believe this starts in the boardroom. Unfortunately, we believe the current long-tenured Board has adopted an entrenched mindset and antiquated corporate governance policies that have been to the detriment of the Company's stakeholders. Our three highly qualified nominees, Mark Bassett, Pat Gottschalk and Keith Rosenbloom, will bring the operational acumen and independent perspectives needed to drive better margins, enhance stockholder value and increase transparency at AVD. We urge stockholders to vote on the BLUE card to elevate AVD today."

07:38 EDT Statera BioPharma, Lay Sciences intend to enter strategic partnership - Statera Biopharma announced that the company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc., a development and commercialization company of innovative solutions, to license worldwide manufacturing rights to certain Lay Sciences' IgY products containing avian antibodies as an active ingredient. "The strategic partnership with Lay Sciences has the potential to produce near term revenue," said Michael K. Handley, President and CEO of Statera Biopharma. "The agreement allows Statera the right to supply the products for the existing approved markets. Statera also receives the right to license and commercialize current and future products for other indications." Under the terms of the proposed agreement, Lay Sciences would receive an upfront payment comprised of both equity and cash and would also have the potential to earn royalties and milestones associated with the development of IgY in gastrointestinal and upper respiratory indications.

07:35 EDT BridgeBio sells rare pediatric disease priority review voucher for $110M - BridgeBio Pharma announced that it has entered into a definitive agreement with an undisclosed purchaser to sell its PRV for $110M. The company received the voucher in February 2021 under a U.S. FDA program intended to encourage the development of treatments for rare pediatric diseases. BridgeBio was awarded the voucher when its affiliate, Origin Biosciences Inc., received approval of NULIBRY for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A. The sale is subject to customary closing conditions and is expected to occur following the expiration of applicable U.S. antitrust clearance requirements. In connection with the PRV sale, BridgeBio has executed an amendment to its existing senior secured credit facility, extending the interest-only period by two years and principal repayment to November 17, 2026. The company received consent for the PRV sale from its lenders with all proceeds retained by BridgeBio. BridgeBio retains access to up to $100M in delayed debt draws through year end 2022, subject to certain conditions. The amendment was approved unanimously by existing lenders in the syndicate without adjusting pricing and without imposing financial covenants. "The sale of this voucher will help us advance our pipeline of drug development programs targeting genetic diseases and cancers," said Brian Stephenson, Ph.D., CFA, BridgeBio's CFO. "We believe this deal, coupled with our amended loan agreement, offers us the opportunity to read out more data within the duration of our debt and advance meaningful medicines to patients in need in the years to come."

07:34 EDT Nielsen announces expiration of go-shop period - Nielsen (NLSN) announced the expiration of the 45-day "go-shop" period under its definitive agreement to be acquired by a consortium of private investment funds led by Evergreen Coast Capital, an affiliate of Elliott Investment Management L.P., and Brookfield Business Partners (BBU), together with institutional partners. Nielsen and its representatives were permitted to solicit and consider alternative acquisition proposals from third parties until May 12. Nielsen representatives ultimately contacted over 30 parties, representing a mix of financial and strategic parties. As of expiration of the "go-shop" period, no alternative proposals were submitted. Consistent with the Transaction Agreement, Nielsen expects to file its preliminary proxy statement in connection with the related shareholder vote to approve the transaction on or around May 19. The transaction remains subject to approval by Nielsen shareholders, regulatory approvals, consultation with the works council, and other customary closing conditions. If the closing conditions are met, the transaction is expected to close in the second half of 2022.

07:32 EDT RYB Education announces approval of name change - RYB Education announced that it has changed its name "RYB Education, Inc." to "Gravitas Education Holdings, Inc." with the approval by its shareholders at the extraordinary general meeting held on March 13. The American Depositary Shares, each representing one Class A ordinary share of the company, par value US$0.001 per share, of the company, are expected to begin trading under the new corporate name on or about May 24. The company's ticker will change from "RYB" to "GEHI" on or about May 24.

07:21 EDT RF Industries appoints Ray Bibsi as COO - RF Industries announced two changes to its leadership structure to support the integration of its recently announced acquisition of Microlab/FXR LLC and the Company's move to the next phase of its business plan to support continued growth. Ray Bibisi has transitioned to the role of COO of RF Industries, where he will work closely with Robert Dawson, CEO of RF Industries, on the Company's overall strategy and execution. Mr. Bibisi will play a key role in driving the company's continuous improvement efforts around maximizing operational efficiencies including lean principles, automation, and manufacturing consolidation, while managing supply chain rationalization and optimization initiatives. He will also oversee the transformation efforts around harmonizing the Company's ERP system, along with other IT platforms and services. Bibisi joined RF Industries as CRO in January 2020. In addition, Christophe Massenet has been promoted to VP of Technology and Engineering at RF Industries. In this newly created role, reporting to the CEO, Mr. Massenet will lead a new centralized technology and engineering office that will oversee the product and technology roadmaps across the entire Company, as RF Industries continues to add innovative products and solutions to its overall portfolio. He will lead a team of technology experts from across the Company including key technical and engineering experts that joined in the recent acquisition of Microlab. Massenet previously served as VP of Engineering and Operations at Schroff Technologies International.

07:16 EDT Nouveau Monde provides quarterly update amid shift in market conditions - Nouveau Monde Graphite completed another quarter of diligent progress towards the establishment of what is projected to be North America's largest and first fully integrated ore-to-battery-material natural graphite production in a context of accelerated growth in the battery space and sustained pressure on supply chains. NMG maintained its focus on the completion of its Phase-1 production line with the construction of its coating unit and the advancement of its Phase-2 operations through process optimization, engineering, procurement planning, preparatory work and updated economics modelling. New variants of COVID-19 forcing lockdowns in China, the Russia-Ukraine war as well as continued consumer enthusiasm for cleantech are creating significant pressure on raw materials sourcing for battery and electric vehicle manufacturers. As supplies tighten, demand continues to increase, with now more than 6,200 GWh of global lithium-ion battery production capacity expected by 2031. Correspondingly, projections forecast a flake graphite deficit of nearly 2 million tonnes per annum by the end of the decade. Current market conditions combined with engagement reaping from NMG's marketing program have led to enhanced activities with potential tier-1 customers in 2022 with a view to securing a long-term cornerstone offtake agreement for its anode material. Production at Phase-1 facilities and testing at NMG's new laboratory enable the supply of graphite products in a variety of specifications to meet the individual requirements of each manufacturer. NMG has advanced into the qualification process with several battery manufacturers, now providing A & B samples. Sustained interest from potential top-tier customers is supported by quality checks, site visits to the Company's Phase-1 operations and requests for information. Interest in NMG's high-purity advanced materials stems from industry leaders as North American production enters a growth phase and raw materials supplies become constrained. Indeed, rising anode demand, interrupted graphite production in China due to COVID-19, and global logistics disruptions have driven year-over-year flake graphite prices up 34.6%. Original Equipment Manufacturers are turning their attention upstream to secure sourcing and reduce their risks. Through direct development, joint ventures or strategic alliances, processing and mining are now gaining manufacturers' attention. NMG's proprietary coating process is taking shape at the Company's Phase-1 demonstration plant. With key deliveries having all been received, construction is advancing safely, efficiently and on budget for targeted commissioning by the end of H1-2022. This unit is set to complete NMG's production line, from ore to anode material, for a 2,000 tpa nameplate capacity. Production of spherical purified graphite continues via NMG's shaping and purification modules. Site preparation is now completed at the Company's facility ahead of the delivery and installation of the new state-of-the-art shaping unit expected to be delivered towards the end of Q2-2022. In parallel, the Front-End Loading feasibility engineering analysis for the Company's Phase-2 operations is progressing and on budget, with a 75% completion rate and a scheduled completion by the end of Q2-2022. NMG's integrated business model will be reflected in this National Instrument 43-101 Standards of Disclosure for Mineral Projects-compliant feasibility study for the Phase-2 Becancour Battery Material Plant to update planning, cost projection, and development framework in a unified structure with the Matawinie Mine. In complement to the engineering efforts, the Company has initiated the permitting planning process and community outreach for the Becancour Battery Materials Plant. Continued progress of detailed engineering and optimization for the construction of the Phase-2 Matawinie Mine, notably on overall site layout, concrete lots, steel and architecture drawings, support buildings, compressed air and mechanical components, are progressing, supported by the finalization of process design parameters, civil infrastructure plans and specifications emissions for construction and equipment selection. In preparation of the mining infrastructure, tree clearing activities and implementation of environmental protection infrastructure resumed in Q1-2022 to prepare the site for the next phase of civil works. As part of its electrification strategy, the Company is working with Caterpillartowards the development, testing and production of Cat "zero-emission machines" for the Matawinie Mine. Caterpillar's and NMG's technical teams are actively engaged in assessing technology opportunities and planning the all-electric fleet for the Phase 2 Matawinie Mine.

07:12 EDT Guardforce subsidiary launched new cyber-security marine scanning service - Guardforce AI announced that Handshake Networking Limited, a subsidiary of the Company, has developed an automated marine scanning service designed to address key security vulnerabilities in the maritime transportation industry. The Company also announced it has launched this new service with one of the world's leading operators of global container vessels based in Hong Kong. Terence Yap, Chairman of Guardforce AI, stated, "We are pleased to announce the launch of our automated marine scanning platform with one of the premier operators of global container vessels. Prior to our selection, our new automated marine scanning service was heavily evaluated by this customer, providing strong validation of the robustness of this cyber intelligence offering and application within the maritime transportation industry. With rapid digitalization of the industry, more and more global shipping companies have come to realize the economic impact of cybercrimes and the need for efficient solutions to help prevent these risks. Cybersecurity solutions are more urgent than ever as International Maritime Organization regulation requires that all vessels and ships worldwide include cyber risk management in their safety management systems in accordance with the International Safety Management code. Cybersecurity attacks represent an unprecedented threat to the shipping industry, as well as to the global community, and we anticipate that the demand for our solutions will continue to grow."

07:10 EDT IMV Inc. announces selected upcoming milestones - Maveropepimut-S: Q3 2022: Early data look for the open label VITALIZE Phase 2 DLBCL trial; Q3 2022: Initiate enrollment in AVALON Phase 2b trial in platinum-resistant ovarian cancer; Q4 2022: Early data look for the investigator-initiated breast cancer trial; H1 2023: Early data look from the AVALON trial in platinum resistant ovarian cancer. DPX-SurMAGE: Q4 2022: Early data look from Phase 1 Non-muscle invasive bladder cancer study in Canada.

07:07 EDT Humacyte sees cash, equivalents funding operations through end of 2024 - The company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the company's current expected timelines for potential approvals of the HAV in vascular trauma and AV access for hemodialysis.

07:03 EDT Better Therapeutics announces expected upcoming milestones - Completion of BT-001 Pivotal Trial and De Novo Submission: Secondary endpoint data following 180 days of treatment are expected at the end of the second quarter of 2022. In addition to the secondary endpoint which compares the mean change in A1c between the treated group to the control group, exploratory endpoints will include a comparison of the change in medications of the two groups. With continued positive data, the company expects to file a de novo classification request with the FDA in the third quarter of 2022, seeking marketing authorization of BT-001 for the treatment of patients with type 2 diabetes. Real World Evidence Study: Data are expected on the first 250 patients to complete 90 days of treatment in the fourth quarter of 2022. BT-002 and BT-003 Pivotal Trials: The company will gather pilot data from the BT-001 study that will inform the initiation of pivotal trials of BT-002 and BT-003 for the treatment of hypertension and hyperlipidemia, respectively. Pending favorable data and sufficient capital, these studies will commence as soon as the first half of 2023. Key Opinion Leader Webinar: The company will host a key opinion leader webinar concurrent with the ADA annual meeting being held June 3-7, 2022. The webinar will explain the use of nCBT as a mechanism of action, the intersection of clinical intent, behavioral science and designing software for behavior change. It will then connect the dots and demonstrate how nCBT can fill the gap in current standard of care guidelines. Participating KOL's will be announced at a later date.

07:01 EDT Maverix on track to achieve 2022 guidamce of 32K-35K attributable GEOs - Maverix is on track to achieve its previously announced guidance of 32,000 to 35,000 attributable GEOs for 2022 at approximately a 90% cash margin with approximately 99% of expected revenue derived from gold and silver. Similar to 2021, the Company expects attributable GEOs to increase in the second half of the fiscal year.

06:48 EDT Medtronic completes acquisition of Intersect ENT - Medtronic (MDT) announced that it has completed the acquisition of Intersect ENT (XENT), expanding the company's comprehensive ear, nose, and throat portfolio with products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps. As a result of the close of the transaction announced on Aug. 6, 2021, Medtronic has acquired Intersect ENT's PROPEL and SINUVA sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility. Intersect ENT employees also join Medtronic through this acquisition. A former Intersect ENT brand, Fiagon, was divested simultaneously at close, and those products Cube navigation system and VenSure balloon sinus dilation system were not included in the acquisition. Intersect ENT's product lines and customer base will further the efforts of Medtronic to have a positive impact for patients who suffer from chronic rhinosinusitis. CRS is one of the most common health care problems in the U.S., with approximately 30 million adults diagnosed annually. It has been associated with lost days of work, decreased productivity, and even depression and anxiety, with most patients reporting 5-15+ years of suffering and medical treatment. Through this acquisition, Medtronic gains PROPEL and SINUVA, which are unique bioabsorbable, steroid-eluting implants for sinus patients. PROPEL implants are inserted following endoscopic sinus surgery to maintain sinus patency and provide localized steroid delivery. SINUVA implants are designed for use in the physician's office setting for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery. PROPEL, PROPEL Mini, and PROPEL Contour implants are FDA approved in the U.S. and CE marked in the EU. SINUVA Sinus Implants are currently sold only in the U.S.

06:32 EDT Teleflex announces full U.S. commercial launch of UroLift 2, UroLift ATC - Teleflex announced the full U.S. commercial launch of its UroLift 2 System and UroLift ATC System, and that it will update the urology community through multiple in-booth presentations at the 2022 American Urological Association annual meeting. The conference will take place in-person from May 13-16 in New Orleans. The UroLift 2 System offers an improved workflow, including an ergonomic single trigger and an improved suture cutter in a reduced device and packaging footprint. The UroLift ATC System provides physicians with an enhanced delivery tip specifically designed to effectively treat patients with an obstructive median lobe.

06:11 EDT Nordic American Tankers takes delivery of Suezmax tanker - Nordic American Tankers has taken delivery of a Suezmax tanker from the Samsung shipyard in South Korea. The vessel is about 150,000 tons. The new Suezmax will commence a contract for six years to ASYAD Shipping Company of the Sultanate of Oman. The contract is producing earnings and cashflow as from delivery from the yard. Another newbuilding from Samsung is coming at the end of June. This vessel also has a contract for six years to the Sultanate of Oman.

05:56 EDT Posco signs agreement to invest in Prologium - Posco has decided to cooperate with Prologium solid-state battery manufacture, to develop core materials for next-generation secondary batteries. Posco signed an agreement on the 12th to invest in Prologium and to co-develop cathode materials, silicon cathode materials, solid electrolytes for solid-state batteries, and establish a global supply system. Founded in 2006, Prologium developed solid-state batteries in 2012 and is selling them to manufacturers of small IT devices such as smartwatches. The company is also attracting investment from global investment companies and co-developing solid-state batteries for electric vehicles with major automakers such as Mercedes-Benz Group AG.

05:53 EDT JinkoSolar signs first European ESS agreement with Memodo GmbH - JinkoSolar announced that it has signed its first European Energy Storage Solution agreement with Memodo GmbH. The Memodo exclusivity agreement for JinkoSolar's ESS product portfolio will cover the D-A-CH region, Germany, Austria and Switzerland, for 2022 and 2023, respectively, which includes an all-in-one system, a stackable low-voltage and high-voltage storage system and a single or three-phase hybrid inverter. All power storage devices are installed with lithium iron phosphate batteries and are compatible with well-known inverters.

05:47 EDT Musk: Twitter deal 'temporarily on hold' pending details - Elon Musk said via Twitter: "Twitter deal temporarily on hold pending details supporting calculation that spam/fake accounts do indeed represent less than 5% of users." Reference Link